Welcome to Pharmalicensing Partnering Update...

Pharmalicensing.com

Send to a colleague

21st May 2013

Welcome to Pharmalicensing Partnering Update...

Licensing Opportunities
In-licensing Needs
Company Profiles
Company Releases
Industry events

Pharmalicensing recommends... Modified hydroxyapatite (HA) products, biomaterials and applications for the improvement of bone/tooth repair products and implant anchoring Scientists have developed novel biomaterials comprising of modified hydroxyapatite (HA) which can be used to improve bone, dental and oral health products as well as implant anchoring into the body more Novel, ready-to-market, next generation of pain relief patch product sought for topical analgesic leader Our analgesic specialists are seeking a new, innovative and novel patch product for the treatment of pain to add to their portfolio more Topical OTC (Europe) and Rx (United States) pain relief product Using a unique resin-based topical delivery system, this product provides more effective local pain relief and longer periods of sustained relief compared to existing products more Unique “Plant Milking” Technology capable of producing high value active cosmetic compounds from the roots of rare, protected, slow to grow plant species The ‘green technology’ allows the extraction of cosmetically active compounds from plants using root exudation without harming the plants involved more BioVaria 2013 June 4 Munich, Germany The 6th BioVaria will take place on 4 June 2013 in Munich. Thirteen technology transfer organizations from all over Europe have selected the best, licensable life-science projects from their partner institutes: potential diagnostics and therapeutics, as well as platform technologies. The proven BioVaria format with its short presentations and poster exhibition gives industry representatives a good overview and allows plenty of opportunity for individual discussions with scientists and their technology transfer representatives. As in 2011, there will also be a Spin-off Panel for European start-ups who will present their business to a jury of top experts in an interactive format. Registration, technologies and spin-offs at: www.biovaria.org
Licensing Opportunities Allergy Unique and efficient allergic rhinitis therapy available for licensing Hexabrix, the contrast material used in the study thus far, has also proven to be effective for atopic dermatitis/eczema in a mouse model and for allergic conjunctivitis in a rat model more Biotechnology Generating definitive endoderm and hepatic/pancreatic progenitors from human embryonic stem cells This technology comprises the step-wise differentiation of human embryonic stem cells (hESCs) towards multipotent organ progenitors of the liver and pancreas lineages more Blood and forming organs Blaze medical devices - blood analyzer Device and consumables for measuring blood product degradation more Cardiovascular Inno-C08001 (Carvedilol CR) Inno-C08001 is indicated for the treatment of hypertension, heart failure and left ventricular dysfunction following myocardial infarction more Central Nervous System Inno-C07001(levodopa, carbidopa, entacapone) A combination drug of three active ingredients for the treatment of parkinson’s disease more Naloxone 0,4 mg/ml ampoule Opioid receptor antagonist reducing opioid induced respiratory depression more Tetrabenazine 25 mg tablets Treatment of movement disorders associated with organic central nervous system conditions, e.g. huntington's chorea, hemiballismus and senile chorea more Transdermal Fentanyl Fentanyl patch for the management of severe pain in patients who require continuous opioid analgesia more Transdermal Rivastigmine Transdermal system for mild to moderate dementia of the alzheimer's type and for management of mild to moderate dementia associated with parkinson 's disease more Dermatological AS-22 : breakthrough treatment of bedsores, diabetic ulcers and venous leg ulcers AS-22 is a hypertonic, non-specific MMP-inhibiting, hydrating & cleaning solution to treat bedsores, diabetic ulcers, and venous leg ulcers. Reduces pain and promotes fast healing, even in case of refractory wounds more Topical diclofenac products Topical diclofenac formulations for the treatment of inflammatory and painful conditions more Drug delivery Biodegradable thermogelling polymer Polymer systems are being developed for in-vivo applications, including drug delivery vehicles for controlled release of drugs when implanted in a subject’s body more Biodegradable triblock cipolymers, synthesis methods therefor, and hydrogels and biomaterials made Our drug delivery system includes a hydrogel formed from cyclodextrin and an amphiphilic copolymer. Copolymers can be formulated to be bioabsorbable, biocompatible, and are capable of forming hydrogel with cyclodextrin more Cellophil™ biomedical polymers - new and superior biomedical polymers for drug delivery and new standards in the medical device industry Cellophil™ is a platform of novel polymers based on amino-acid groups. The platform polymers show superior biocompatibility and can be loaded with drugs for controlled release more Injectable drug delivery system with cyclodextrin-polymer based hydrogels Our cyclodextrin-polymer based injectable hydrogel comprises of cyclodextrin, which is biodegradable, biocompatible and may be naturally or artificially synthesized more The TDS technology Readily formulated, rapidly absorbed, broadly applicable liquid transdermal delivery enabling sprayed-on, rubbed-in, rapidly effective products across therapeutic categories. No patch or device required, only a low-cost, readily available metered pump more Drug discovery 3D Biomatrix - three dimensional (3D) cell culture technology Bio-mimicking (3D cell culture) research tools for drug development more DataSpeaks - new science for precision medicine New science solutions for clinical development more Gastrointestinal Secretory IgA - a new treatment for clostridium difficile Orally-administered passive immunization with semi-synthetic polyclonal human secretory IgA more Genito-urinary Hp-GY for the treatment of genital herpes and bacterial infection (vaginosis) Hp-GY eliminates viral & bacterial contaminants, resulting in reduction of lesion size and accelerated recovery. It also treats bacterial vaginosis, regulating vaginal pH and flora, and providing hydration and relief more Rapid detection of urinary tract infection A novel diagnostic technology for urinary tract infection. Infectious diseases remain one of the greatest challenges to global health. Urinary tract infection (UTI) is considered to be the most common bacterial infection more Hospital and Surgery Droperidol 1.25mg/1ml ampoule Injectable for treatment of PONV and nausea and vomiting during post-operative PCA more Esmolol 100mg/10ml vial Ultrashort acting beta blocker esmolol for use in anesthesia, intensive care, cardiology and internal medicine more ViaDerm - device-tissue biointegration platform Tissue engineered skin access device more Infectious diseases Cyclic peptides for HIV vaccination Synthetic cyclic peptides as a compound of an HIV-1 vaccine. AIDS remains a major health issue worldwide. 30 millions peoples have died from the disease caused by the HIV-1 virus more Musculoskeletal LT- NS001 (naproxen etemesil), a patented bio activated prodrug of Naproxen with a superior GI profile compared to other NSAIDs LT-NS001, is an NSAID pro-drug for the treatment of chronic inflammatory conditions, such as osteoarthritis. Multiple phase I trials demonstrated its safety and proof of concept more Oncology Anti-cancer immunotherapy: anti-tumor vaccines Novel peptide sequences identified from breast, prostate, and bladder cancers are utilized as targets for anti-tumor vaccines more Development of histone methylation inhibitor DZNep analogues for anti-cancer therapy DZNep, a S-adenosylhomocysteine hydrolase (SAHH) inhibitor that is also a histone methylation inhibitor, has been shown to possess anti-cancer effects by selectively inducing apoptosis in cancer and transformed cells but not in normal cells more Novel peptides which serve as mobilization agents New peptides for improving the recruitment of stem cells for transplantation.Blood cancers (leukemia, lymphoma and myeloma) are very common: they accounted for nearly 9.5 percent of deaths in the US from cancer in 2009 more Novel variants of ErbB ligands for treating cancer Novel splice variants of ErbB ligands for treating ErbB receptor-mediated diseases such as cancer. Receptor tyrosine kinases play a key role in the dissemination of cell to cell signaling in organisms more Oral Health Orosol for the treatment of radio and chemotherapy-induced oral mucositis The first topical protease inhibitor with antibacterial properties discovered and patented by Vitro-Bio more Respiratory VB-TH4: First preventive & curative topical antiviral, antibacterial and expectorant spray for viral throat infection Spraying a tannin-rich hypertonic solution on the throat surface generates hypotonic fluid exudation, detaching all contaminants, hydrating the throat and alleviating the pain. Virus neutralization inhibits further infection. For adults and children more
In-licensing Needs Diagnostic Easy-to-use diagnostic kits to diagnose consumer health related conditions A global health care group is currently seeking technologies that are able to diagnose health related conditions in consumers more Drug delivery Oral dissolving thin film technology with high API loading capabilities A global OTC healthcare company is currently seeking orally dissolving thin film technologies with capabilities to load high amounts of active pharmaceutical ingredients (APIs) greater than 100mg more Orally delivered modified release drug delivery systems to overcome first-pass metabolism A global OTC drug products group with offices in the UK is seeking orally delivered modified release drug delivery systems that extend the efficacy of active pharmaceutical ingredients (APIs), which are susceptible to a large first-pass metabolism more Company profiles Bionow Bionow is an award winning business development and services organisation focussed on rewarding biomedical companies across the North of England through active engagement and product/service savings CIS Pharma - Chemisches Institut Schaefer Drug delivery systems and medical devices research Exploit Technologies ETPL is the technology transfer arm of Singapore’s Agency for Science, Technology and Research (A*STAR) Innopharmax Innopharmax is a specialty pharmaceutical company focused in the treatment of infectious diseases,immunology and oncology via DDS technology to improve safety & effectivene of currently available drug MichBio MichBio is a non-profit industry association whose mission is to drive bio-industry growth in Michigan by providing business resources, education, intelligence and advocacy Yeda R&D Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists Company Releases Beacon launch new website Beacon announces the launch of a new improved website to enhance communications with our stakeholders Beacon launch Streptokinase Beacon Pharmaceuticals Ltd is pleased to announce the launch in the UK of Stretokinase Events
Partnering for Vaccine Emerging Markets 10-11 June 2013 - Berlin, Germany The senior level forum for the world’s vaccine strategists who are seeking partnerships to fulfil local, regional and global market needs. Opportunities in developed, emerging and developing countries are discussed and progressed by CEOs in an easy-to-reach location for all stakeholders. Event Details Email Event Organiser	Nordic Life Science Days 14-15 Oct 2013 - Stockholm, Sweden The Nordic Life Science Days will bring together major European stakeholders, investors, decision makers and business developers. As worldwide leading place for innovation and investments in the bio-economy, the Nordic region invites you to connect, network and partner. Event Details Email Event Organiser

IP Technology Exchange, Inc
2109 East Palm Ave.
Tampa, Fl 33605
Email: info@pharmalicensing.com

IP Technology Exchange, Inc

If you no longer wish to receive this newsletter please unsubscribe